2169919-21-3 Revumenib

Properties

Appearance White to off-white powder
Boiling point:739.1±70.0 °C
Density 1.28±0.1 g/cm3

Application:

   Revumenib (formerly known as SNDX-5613) is a small molecule inhibitor primarily used to treat relapsed or refractory acute leukemia, especially in patients with KMT2A gene rearrangement (MLL rearrangement). Revumenib inhibits cancer cell growth and induces apoptosis by blocking the binding of Menin to KMT2A protein, disrupting the abnormally activated gene expression pathway in leukemia cells.
 

Synonyms:

2169919-21-3

revumenib

N-Ethyl-2-[4-[7-[[4-(ethylsulfonylamino)cyclohexyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl]oxy-5-fluoro-N-propan-2-ylbenzamide

2-({4-[7-({(1r,4r)-4-[(ethanesulfonyl)amino]cyclohexyl}methyl)-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl}oxy)-N-ethyl-5-fluoro-N-(propan-2-yl)benzamide

N-ethyl-2-((4-(7-(((1r,4r)-4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide

Benzamide, N-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-N-(1-methylethyl)-

Hot Tags: 2169919-21-3 revumenib, China 2169919-21-3 revumenib manufacturers, suppliers, Cinacalcet hydrochloride, Olivetol, Pyrantel pamoate, Colchicine, 3 Quinuclidinone hydrochloride, Glycocholic acid